Traws Pharma Files 8-K on Officer Changes & Shareholder Votes

TL;DR

Traws Pharma (formerly Onconova) filed an 8-K detailing director/officer changes and shareholder votes.

AI Summary

Traws Pharma, Inc. filed an 8-K on November 28, 2025, reporting events as of November 21, 2025. The filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. It also includes the submission of matters to a vote of security holders and financial statements with exhibits. The company was formerly known as Onconova Therapeutics, Inc.

Why It Matters

This 8-K filing indicates significant corporate governance and potential strategic shifts within Traws Pharma, Inc., including changes in leadership and matters presented for shareholder approval.

Risk Assessment

Risk Level: medium — Changes in directors and officers, along with matters submitted to shareholders, can signal shifts in strategy or internal dynamics that may impact the company's future performance.

Key Players & Entities

• Traws Pharma, Inc. (company) — Registrant
• Onconova Therapeutics, Inc. (company) — Former company name
• November 21, 2025 (date) — Earliest event reported date
• November 28, 2025 (date) — Filing date

FAQ

Filing Documents

• tm2532319d1_8k.htm (8-K) — 52KB
• tm2532319d1_ex10-1.htm (EX-10.1) — 110KB
• 0001104659-25-116962.txt ( ) — 352KB
• tmb-20251121.xsd (EX-101.SCH) — 3KB
• tmb-20251121_lab.xml (EX-101.LAB) — 33KB
• tmb-20251121_pre.xml (EX-101.PRE) — 22KB
• tm2532319d1_8k_htm.xml (XML) — 3KB

02 Departure of Directors or Certain

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As described in Item 5.07 below, on November 21, 2025, at the 2025 Annual Meeting of Stockholders (the "Annual Meeting") of Traws Pharma, Inc. (the "Company"), the Company's stockholders approved the amendment and restatement of the Company's Amended and Restated 2021 Incentive Compensation Plan (as so amended and restated, the "Amended Plan"), to increase the number of shares of common stock reserved and authorized for issuance thereunder by 1,500,000 shares and extend the term of the Amended Plan until November 20, 2035. The Amended Plan was previously approved by the Company's Board of Directors, subject to stockholder approval, on October 7, 2025. The Amended Plan became effective on November 21, 2025 following receipt of stockholder approval. Additional information regarding the Amended Plan is set forth in the Company's Definitive Proxy Statement on Schedule 14A (the "Proxy Statement") filed by the Company with the Securities and Exchange Commission on October 8, 2025, which information is incorporated herein by reference. Such information and the foregoing description of the Amended Plan do not purport to be complete and are qualified in their entirety by reference to the full text of the Amended Plan, a copy of which is attached to this Current Report Exhibit 10.1 and is incorporated herein by reference.

07 Submission of Matters to a Vote

Item 5.07 Submission of Matters to a Vote of Security Holders. On November 21, 2025, the Company held the Annual Meeting in a virtual format. At the close of business on October 2, 2025, the record date for the Annual Meeting, there were 7,125,832 shares of Company common stock issued and outstanding, which constituted all of the issued and outstanding shares of capital stock of the Company entitled to vote at the Annual Meeting. At the Annual Meeting, 3,419,727 of the Company's 7,125,832 outstanding shares of common stock entitled to vote as of the record date, or approximately 48.0%, were represented by proxy or in person (virtually), and, therefore, a quorum was present. The proposals voted on at the Annual Meeting are more fully described in the Proxy Statement, which information is incorporated herein by reference. The final voting results on the proposals presented for stockholder approval at the Annual Meeting were as follows: Proposal 1: To elect seven directors, each to hold office until the Company's 2026 Annual Meeting of Stockholders and until his or her successor is elected and qualified. Each nominee for director was elected by a vote of the stockholders as follows: Nominee Votes For Withheld Broker Non-Votes Iain Dukes, D.Phil. 2,366,179 37,016 1,016,532 Werner Cautreels, Ph.D. 2,364,118 39,077 1,016,532 Trafford Clarke, Ph.D. 2,364,172 39,023 1,016,532 John Leaman, M.D. 2,367,095 36,100 1,016,532 Nikolay Savchuck Ph.D. 2,364,157 39,038 1,016,532 M. Teresa Shoemaker 2,362,913 40,282 1,016,532 Jack E. Stover 2,363,812 39,383 1,016,532 Proposal 2: To consider and vote upon the amendment and restatement of the Company's 2021 Incentive Compensation Plan, as amended and restated. The proposal to approve the Amended Plan was approved by a vote of the stockholders as follows: Votes For Votes Against Abstentions Broker Non-Votes 2,136,875 242,566 23,754 1,016,532 Proposal 3: To approve, on an advisory b

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 28, 2025 TRAWS PHARMA, INC. By: /s/ Iain Dukes Iain Dukes Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR